Generate Biomedicines

GENB · NASDAQ

$12.90+$0.34 (+2.71%)TodayMarket closed ·
Prev close $12.56

Who owns GENB

Largest institutional holders, from their latest 13F filings

The 10 largest institutions hold 77.2% of GENB’s shares.

  • Flagship Ventures48.9%
  • Flagship Funds9.9%
  • Fidelity Management & Research Company LLC4.1%
  • Capital World Investors3.3%
  • Next 6 largest institutions11.0%
  • All other shareholders22.8%
Top institutional holders of GENB
HolderShares% of shares
Flagship Ventures62.67M48.89%
Flagship Funds12.72M9.93%
Fidelity Management & Research Company LLC5.22M4.07%
Capital World Investors4.22M3.29%
Braidwell LP3.28M2.56%
Nally (Michael)2.89M2.25%
T. Rowe Price Associates, Inc.2.14M1.67%
Norges Bank Investment Management (NBIM)2.09M1.63%
ARCH Venture Partners1.94M1.52%
HarbourVest Partners, L.L.C.1.72M1.34%

Largest mutual fund holders

Top mutual fund holders of GENB
HolderShares% of shares
American Funds SMALLCAP World Fund3.75M2.93%
Statens Pensjonsfond Utland2.88M2.24%
ARK Genomic Revolution ETF1.62M1.26%
Fidelity Growth Company Fund841.59K0.66%
Vanguard Total Stock Market Index Fund816.88K0.64%

Insider trades

Form 4 filings by officers, directors and large holders

Over the last 6 months, insiders sold $16.00K (1 trade) of GENB on the open market, with no buys.

Latest GENB insider transactions
InsiderTypeSharesValue
ARNOLD FRANCESSale1.00K$16.00K

Short interest

Settled Sep 30, 2026

Shares short
7.42M
Days to cover
5.75
% of shares outstanding
5.79%
Average daily volume
1.29M
Change since last report
+3.3%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.